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https://doi.org/10.1016/j.celrep.2020.107647SUMMARYThe NIPBL/MAU2 heterodimer loads cohesin onto chromatin. Mutations in NIPBL account for most cases of
the rare developmental disorder Cornelia de Lange syndrome (CdLS). Here we report aMAU2 variant causing
CdLS, a deletion of seven amino acids that impairs the interaction betweenMAU2 and the NIPBL N terminus.
Investigating this interaction, we discovered that MAU2 and the NIPBL N terminus are largely dispensable for
normal cohesin and NIPBL function in cells with a NIPBL early truncating mutation. Despite a predicted fatal
outcome of an out-of-frame single nucleotide duplication in NIPBL, engineered in two different cell lines,
alternative translation initiation yields a form of NIPBLmissing N-terminal residues. This form cannot interact
with MAU2, but binds DNA and mediates cohesin loading. Altogether, our work reveals that cohesin loading
can occur independently of functional NIPBL/MAU2 complexes and highlights a novel mechanism protective
against out-of-frame mutations that is potentially relevant for other genetic conditions.INTRODUCTION
Cohesin is a highly conserved protein complex essential for cell
survival. In humans, the complex is composed of three struc-
tural core subunits named SMC1A, SMC3, and RAD21, which
together form a ring-shaped structure that topologically encir-
cles DNA (Haering et al., 2008; Murayama and Uhlmann,
2014). This ability allows cohesin to carry out a large spectrum
of chromatin-related functions, including sister chromatid cohe-
sion, DNA repair, transcriptional regulation, and three-dimen-
sional organization of chromatin (Zhu and Wang, 2019). In order
to accomplish these essential tasks, cohesin needs to interact
with chromatin. Cohesin’s binding to DNA depends on a heter-
odimer formed by NIPBL and MAU2, also known as cohesin
loader or kollerin complex (Ciosk et al., 2000; Watrin et al.,This is an open access article under the CC BY-N2006). Importantly, NIPBL is also known to play a role in tran-
scriptional regulation independently of cohesin (Zuin et al.,
2014). The interaction with cohesin is mediated by the C termi-
nus of NIPBL (Chao et al., 2015), and mutations affecting this
domain result in reduced interaction between NIPBL and
RAD21 (Kikuchi et al., 2016). The interaction between NIPBL
and MAU2 is mediated by their respective N termini; precisely,
the first 38 amino acids of NIPBL interact with amino acids 32–
71 of MAU2 (Braunholz et al., 2012; Chao et al., 2015). Recent
evidence suggested that MAU2 is required for the correct
folding of the N terminus of NIPBL and that NIPBL is unstable
in the absence of MAU2 (Chao et al., 2015; Hinshaw et al.,
2015). RNA interference experiments similarly demonstrated
that depletion of NIPBL greatly reduces the cellular levels of
MAU2 (Watrin et al., 2006), consistent with the notion that theCell Reports 31, 107647, May 19, 2020 ª 2020 The Authors. 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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stability.
Variations in the NIPBL gene are the most frequent cause of
Cornelia de Lange syndrome (CdLS; Online Mendelian Inheri-
tance in Man [OMIM] #122470), a multisystem developmental
disorder characterized by growth retardation, intellectual
disability, developmental delay, limb anomalies, and distinctive
facial features (Kline et al., 2007). CdLS was recently grouped
into the category of the so-called transcriptomopathies, as a
global dysregulation of gene expression was detected in cells
of CdLS patients (Yuan et al., 2015). NIPBL haploinsufficiency
is reported in approximately 70% of patients (Borck et al.,
2004; Gillis et al., 2004; Selicorni et al., 2007), while up to 15%
of cases are collectively accounted for by mutations in cohesin
genes (SMC1A,SMC3,RAD21, andHDAC8) and additional tran-
scriptional regulators or chromatin remodelers (Deardorff et al.,
2012; Gervasini et al., 2013; Gil-Rodrı´guez et al., 2015; Kaiser
et al., 2014; Parenti et al., 2016a, 2016b, 2017; Yuan et al.,
2015). How the mutations in NIPBL or the other CdLS genes
lead to the observed phenotypes is not fully understood, but it
is clear that misregulated gene expression plays an important
role (Liu et al., 2009; Mills et al., 2018). Interestingly, mutations
in MAU2 have never been reported so far, although the protein
encoded by this gene is essential for the stability of NIPBL.
Here we describe the first pathogenic variant affectingMAU2.
The mutation, an in-frame deletion resulting in the loss of seven
amino acids, leads to impaired heterodimerization of MAU2 with
NIPBL, hence affecting the stability of both proteins. The clinical
features of the patient with the deletion in MAU2 overlap with
those of patients with CdLS carrying mutations in NIPBL, sug-
gesting a common pathogenic mechanism. To expand upon
this observation, we delved into the relationship between NIPBL
andMAU2, with particular attention on the respective interaction
domains.
Truncating mutations in NIPBL are mostly associated with a
more severe phenotype and with a higher frequency of limb re-
ductions or malformations in comparison with missense substi-
tutions (Selicorni et al., 2007). In apparent contradiction to this
observation, some patients with truncating mutations affecting
the N terminus of NIPBL, its MAU2-interacting region, present
with mild to moderate phenotypes and do not always display
dramatic reduction of the upper limbs (Borck et al., 2004; Nizon
et al., 2016; Oliveira et al., 2010). This observation raises the
interesting possibility that the molecular consequences of
NIPBL-truncating mutations might depend on their position
along the protein sequence. To test this hypothesis, we used
genome editing to generate a homozygous early truncating mu-
tation inNIPBL in two different cell lines. By this, we observed the
expression of an N-terminally truncated NIPBL by the use of an
alternative translation start site. This N-terminally truncated
NIPBL is able to mediate cohesin loading and does not depend
on MAU2 for its stability. Actually, MAU2 levels are dramatically
reduced in the edited cells. Analogously, a dramatic reduction of
MAU2 but not of NIPBL was observed in the cell line of a CdLS
patient with a NIPBL splice site variant that should lead to an
early truncation of NIPBL. Altogether, our data point to the exis-
tence of a protective mechanism that dodges the deleterious ef-
fects of certain NIPBL mutations and might contribute to the2 Cell Reports 31, 107647, May 19, 2020phenotypical variability associated with different NIPBL-trun-
cating variants.
RESULTS
Whole-Genome Sequencing Identifies the First MAU2
Mutation
Trio whole-genome sequencing was performed on a group of 15
patients with clinical diagnosis of CdLS and negative for muta-
tions in the five known CdLS genes. One putative pathogenic
variant inMAU2 was identified in a patient with a severe pheno-
type and typical CdLS facial dysmorphism (for a detailed clinical
description, see Human Subjects in STAR Methods).
The mutation, an in-frame deletion of 21 nucleotides in
MAU2, results in the loss of seven amino acids: RefSeq
NM_015329, c.927_947del, p.(Gln310_Ala316del). The variant
was found in 34% of the sequencing reads, and Sanger
sequencing confirmed its de novo origin (Figures 1A and 1B).
Comparison of the MAU2 protein sequence across seven spe-
cies showed that the deletion affects a region that is highly
conserved in vertebrate and non-vertebrate animal species
(Figure 1C). To date, de novo missense and nonsense muta-
tions in MAU2 are significantly underrepresented in exome se-
quences (Hinshaw et al., 2015). MAU2 is categorized among
the haploinsufficient genes, with a pLI (probability of intoler-
ance) score of 1, suggesting that the gene is extremely intol-
erant to loss-of-function variations (Lek et al., 2016). Thus,
the mutation identified in the patient of our cohort might repre-
sent the first pathogenic variant in MAU2.
TheMAU2 Deletion Impairs the Heterodimerization with
NIPBL
To investigate how the identified deletion could affectMAU2 pro-
tein structure and its ability to bind NIPBL, we performed an in
silico analysis of the co-crystal structure of the S. cerevisiae co-
hesin loader complex Scc2/NIPBL-Scc4/MAU2 (4XDN) (Hin-
shaw et al., 2015).
On the basis of a previous comparison of the MAU2/Scc4 pro-
tein sequence from yeast to human (Watrin et al., 2006), wemap-
ped the deleted region on the Scc2/NIPBL-Scc4/MAU2 crystal
structure from S. cerevisiae (Figure 1D). The deletion affects
highly conserved amino acids in a helix that is part of the TPR
array that envelops the N terminus of NIPBL. The deletion
removes part of a helix that contacts directly the Scc2/NIPBL
N terminus, likely leading to a distortion of the MAU2-NIPBL
interaction (Figure 1E).
To test this prediction, we introduced the mutation into
expression plasmids to perform quantitative mammalian two-
hybrid interaction assays in HEK293 cells. Constructs encoding
the N-terminal 300 amino acids of NIPBL coupled to the DNA
binding domain of Gal4 were tested for interaction with the
wild-type or mutant full-length MAU2, bound to the activation
domain of NF-kB (Figure 1F). The seven amino acid deletion in
MAU2 caused a reduction of the heterodimerization activity to
46% (Figure 1G). The diminishing effect of the deletion in
MAU2 on its interaction with NIPBL was further confirmed with
a yeast two-hybrid assay. Yeast transformed with mutant
MAU2 showed a slower growth on selective medium, indicative
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Figure 1. Characterization of the MAU2
Deletion Identified in a Patient with CdLS
(A and B) Trio Sanger sequencing (A) and counts
of the genome sequencing run (B) show the
de novo origin of the MAU2 p.(Gln310_Ala316del)
mutation.
(C) Alignment of MAU2 orthologs from different
species shows conservation of the deleted amino
acids (red square) from human to fly.
(D and E) In silico analysis of the cohesin loader co-
crystal structure from S. cerevisiae (4XDN) (Hin-
shaw et al., 2015). (D) The N terminus of Scc2/
NIPBL (red) is enveloped by the TPR repeats of
Scc4/MAU2 (green). The helix fragment corre-
sponding to the deletion Gln310-Ala316 of the
patient is depicted in light blue. (E) The deleted
residues likely interact with residues in the Scc2/
NIPBL N terminus and with regions further into the
structure.
(F and G) Mammalian two-hybrid assay. (F)
Schematic representation of the two-hybrid
assay. Full-length MAU2 wild-type (WT) or the
MAU2 deletion mutant shown in (C) (mut) were
conjugated to the activation domain (AD) of the
mouse NF-kB. The first 300 amino acids of NIPBL
(NIPBL-N300) were conjugated to the binding
domain (BD) of the GAL4 gene. The BD domain
alone served as negative control. (G) Results of the
assay indicate 50% reduction of the interaction
between NIPBL and MAU2 in the presence of the
deletion. Data represent three independent ex-
periments ± SEM.
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MAU2 (Figure S1).
Taken together, these in vitro interaction assays support the in
silico predictions and demonstrate that the MAU2 deletion im-
pairs the interaction between the two subunits of the kollerin
complex.
Gene Expression Changes in MAU2 Mutant Cells and
NIPBL Haploinsufficient Cells Are Similar
Previous assays demonstrated that the interaction between
NIPBL and MAU2 is impaired in the cells of the CdLS patient
carrying the in-frame deletion in MAU2 p.(Gln310_Ala316del).
Because this interaction is essential for NIPBL stability (Chao
et al., 2015; Hinshaw et al., 2015), we hypothesized that the
pathogenic mechanism associated with this mutation in
MAU2 is the resulting instability of NIPBL, which leads to its
haploinsufficiency.
To substantiate our hypothesis, we compared the transcrip-
tome of fibroblasts from the MAU2 p.(Gln310_Ala316del) patient
(male) with fibroblasts from a NIPBL-haploinsufficient patient
(mutation NIPBL p.(Leu1365*), female) and healthy control fibro-
blasts (female). Notably, the patient carrying the nonsense
NIPBL mutation displays a severe CdLS phenotype, in line with
its associated NIPBL haploinsufficiency (Braunholz et al.,
2015). All samples were sequenced in triplicates and genes
locating at the sex chromosomes were omitted from the anal-
ysis. The transcriptomes of the two patients were compared
with that of the control fibroblasts, and the differentially ex-
pressed genes of the patient cells were subsequently correlated.Despite the limitation of this dataset, gene expression changes
clearly correlated between the two patients. This indicates that
overall gene expression is altered in a similar way in cells with
MAU2 and NIPBLmutations (Figure 2A). Among the genes differ-
entially expressed in both patients (p < 0.05), we found 291
genes that were previously found to be misregulated in lympho-
blastoid cells (LCLs) from CdLS patients (Liu et al., 2009). Gene
Ontology (GO) analysis of differentially expressed genes in
MAU2 mutant fibroblasts and NIPBL mutant fibroblasts indi-
cates categories of molecular and cellular functions that are
affected in both cells, such as cell proliferation, cellular move-
ment, tissue development, and regulation of multicellular organ-
ismal development (Figure 2; Table S1).
Cells derived from CdLS patients also show increased sensi-
tivity to DNA damage (Enervald et al., 2013; Vrouwe et al.,
2007). Accordingly, NIPBL was shown to be involved in DNA
damage repair, in both homologous recombination repair, the
pathway involving cohesin (Vrouwe et al., 2007), and non-homol-
ogous end joining (Enervald et al., 2013), the main pathway dur-
ing G1 phase of the cell cycle. To assess whether the diagnosis
of CdLS of theMAU2 patient could be confirmed also at the DNA
repair level, we induced DNA double-strand breaks by gamma
irradiation and quantified the number of gH2AX foci over time
as measure of the breaks and their repair (Figure S2). Repair
occurred with similar kinetics in the control and the different pa-
tient cells and was complete 24 h after irradiation. However, as
the cultured skin fibroblasts were mostly in G1 phase, our results
are informative only about the non-homologous end-joining
pathway.Cell Reports 31, 107647, May 19, 2020 3
A B Figure 2. Transcriptome Analysis of MAU2
and NIPBL Mutant Cells
(A) Scatterplot showing the correlation between
the fold changes of MAU2 mutant fibroblasts
versus control and fibroblasts with NIPBL hap-
loinsufficiency versus control. The Pearson cor-
relation coefficient (R) and the p value (p) are
shown in the graph.
(B) Gene Ontology term analysis of differentially
expressed genes shows overlap in biological
processes between MAU2 and NIPBL mutant
patient fibroblasts. Details for this analysis,
including p values, are shown in Table S1.
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Terminally Truncated NIPBL and Loss of MAU2
MAU2 confers stability to the NIPBL protein through its interac-
tion with the N terminus of NIPBL (Chao et al., 2015; Watrin et al.,
2006). To test whetherMAU2 could have additional functions be-
sides the mere role of ‘‘NIPBL chaperone,’’ we tried to obtain a
stable N-terminally truncated NIPBL that would not require
MAU2 for its stability.
For this purpose, we performed CRISPR-Cas9 genome edit-
ing in HEK293 cells with single guide RNAs (sgRNAs) targeting
exon 2 of NIPBL to obtain early truncating mutations through
the error-prone non-homologous end-joining DNA repair mech-
anism. This resulted in two independently isolated homozygous
clones with the same out-of-frame duplication of T (c.39dup),
predicted to result in the null allele p.(Ala14Cysfs*5) (Figure 3A).
Despite the presence of a homozygous loss-of-function muta-
tion inNIPBL, no difference between wild-type and genome-edi-
ted cells with regard to cell viability and proliferation was
observed.
The amount of cohesin complexes present in these cells
seems to be unaffected, as the levels of the cohesin subunit
SMC3 are unchanged (Figure S3A). However, we observed dif-
ferences for the kollerin complex subunits NIPBL and MAU2.
NIPBL expression was assessed with two different antibodies,
one raised against its N terminus and one recognizing its C ter-
minus. The specificity of the antibodies was tested by knocking
down MAU2 and NIPBL (Figure S3B). The C-terminal antibodies
always produce multiple bands, some specific for NIPBL but
some unspecific (Figure S3B). The knockdown experiment also
clearly confirmed that depletion of MAU2 leads to a strong
reduction of NIPBL and vice versa (Watrin et al., 2006).
In both HEK293 clones carrying the homozygous out-of-frame
duplication in NIPBL, the N-terminal antibody could not detect
any protein. However, wewere able to detect NIPBL in the edited
clones using the C-terminal antibody, suggesting that only the N
terminus of the protein is missing and that an N-terminally trun-
cated form of NIPBL (NIPBLDN) is expressed in the NIPBL
(c.39dup) clones (hereafter called NIPBLDN cells), possibly re-
sulting from the use of an alternative translation initiation site
(TIS). Notably, for the detection of the C terminus of NIPBL, a4 Cell Reports 31, 107647, May 19, 2020combination of antibodies recognizing
different NIPBL isoforms was used, thus
partially explaining the multiple bands
observed in the western blot. Additionaldegradation products of NIPBL as well as possible isoforms
arising from a physiological alternative translation could account
for the additional bands observed (Figures 3B and 3C;
Figure S3B).
NIPBLDN appeared to be less abundant than full-length
NIPBL in the parental cells, suggesting a lower efficiency of the
alternative translation or a reduced stability of NIPBLDN. Impor-
tantly, only a very faint signal could be detected for MAU2,
suggesting an almost total loss of MAU2 in NIPBLDN cells (Fig-
ure 3B). To exclude that the observed rescue of NIPBL could be
specific for HEK293 cells, we introduced the same out-of-frame
duplication of T in the fibrosarcoma cell line HT1080 and
observed again the presence of NIPBLDN and the profound
reduction of MAU2 (Figure 3C). Quantification of the residual
MAU2 protein in both NIPBLDN cell types indicated that MAU2
expression is reduced approximately to 15% in genome-edited
clones (Figure 3D). Co-immunoprecipitation experiments of
MAU2with anti-NIPBL antibodies in HEK293 andHT1080 clones
subsequently showed that the residual MAU2 is unable to
interact with NIPBLDN (Figure 3E).
The presence of NIPBLDN protein in the genome-edited cells
suggested that the mutant transcript escapes nonsense-medi-
ated mRNA decay. Accordingly, Sanger sequencing of the
cDNA obtained fromNIPBLDNcells could detect only themutant
allele (Figure 3A). To expand upon this observation, we
measured NIPBL transcript levels in control and in NIPBLDN
cells using real-time PCRwith two different primer pairs covering
the boundaries between NIPBL exons 2 and 3 and exons 40 and
41. Both primer pairs detected a 1.5- to 1.9-fold increase in
NIPBL mRNA in both NIPBLDN clones compared with parental
cells (Figure S4A). These results are in line with the observation
that the total NIPBL transcript levels never drop below 60% in
cells derived from patients with different NIPBL mutations
(Kaur et al., 2016). This could be due to an incomplete degrada-
tion of the RNA originating from the mutant allele by nonsense-
mediated mRNA decay (Zuin et al., 2017) or to an upregulation
of the intact allele as a mean to compensate for the downregula-
tion of the mutant allele (Kaur et al., 2016). Our results show
increased levels of NIPBL c.39dup transcripts, suggesting a
strong upregulation of both mutant alleles, and the absence of
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Figure 3. Cells with NIPBL Out-of-Frame Duplication Express an N-Terminally Truncated NIPBL and Lack MAU2
(A) Electropherograms of genomic DNA (gDNA) and cDNA of clone 1 (c.1) of the HEK293 edited cells (NIPBLDN cells), showing homozygous duplication of a T in
exon 2 of NIPBL.
(B and C) Blots with nuclear extracts of HEK293WT and NIPBLDN clones (c.1 and c.2) (B) and of HT1080WT and NIPBLDN clones (c.4 and c.15) (C) probed with
antibodies against the N terminus (N-terminal) and the C terminus (C-terminal) of NIPBL. In NIPBLDN cells, NIPBL can only be detected with the C-terminal
antibody that produces multiple bands (bands showing NIPBL are indicated with a line). Detection of MAU2 is only possible in WT cells.
(legend continued on next page)
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MAU2 revealed no significant differences in the total amount of
MAU2 transcript in NIPBLDN cells in comparison with wild-
type cells (Figure S4A). We therefore concluded that MAU2 is
correctly transcribed and translated and that the protein is sub-
sequently degraded because of its inability to interact with
NIPBL. To test which known protein degradation pathway might
be responsible for this degradation, wild-type and NIPBLDN
cells were treated with the proteasome inhibitor MG132, the
lysosomal inhibitor NH4Cl, or the autophagy inhibitor bafilomy-
cin. However, none of these inhibitors could restore the expres-
sion of MAU2 in NIPBLDN cells, ruling them out for the observed
MAU2 degradation (Figures S4B–S4D).
Identification of Alternative TISs
To address whether an alternative TIS would allow initiation of
NIPBL translation in NIPBLDN cells, we established an in vitro
transcription-coupled translation (IVTT) assay. A fragment of
NIPBL cDNA comprising the first 651 bp was inserted into a
pcDNA3.1B vector in frame with a 3xFLAG tag at the 30 end of
the coding sequence. In parallel, the same construct was gener-
ated with the duplication of T (c.39dup). Of importance here, the
30 3xFLAG tag sequence is in frame only with the wild-type
sequence and its canonical ATG but not with that of the mutant
sequence harboring the duplication of T (Figures 4A and 4B). The
resulting plasmids were used as templates in IVTT reactions that
were subsequently analyzed using western blotting. A FLAG
signal was detected in the IVTT products of the wild-type as
well as of the mutant plasmid (Figure 4C), indicating that the
reticulocyte lysate system of the IVTT reaction indeed used an
alternative TIS in the presence of the out-of-frame duplication.
Notably, the wild-type and mutant IVTT proteins displayed only
a very small difference in size (less than 2 kDa), hence indicating
that the alternative TIS must be in close proximity to the canon-
ical ATG. The first ATG after the duplication of T would represent
the most plausible alternative TIS. However, the first ATG is
located 99 amino acids downstream of the duplication. Such a
distance would result in a substantial size difference between
wild-type and mutant IVTT products. Because no such size dif-
ference was observed between the two proteins, we concluded
that the potential alternative TIS had to be located upstream of
the mutation and might result from the shift of the canonical
reading frame (Figure 4A). We identified two new alternative
TISs (aTISs) after shifting the reading frame of one base pair
(aTIS1 and aTIS2; Figure 4B). To determine which of these puta-
tive alternative TISs was actually used, we mutated each aTIS
(ATG>ACG) and performed IVTT (Figure 4C). A FLAG signal
was detected after mutagenesis of aTIS1, whereas the signal
was dramatically reduced for the mutated aTIS2. This indicates
that aTIS2 might be used for the initiation of translation of NIPBL
in the presence of the out-of-frame duplication. The weak FLAG(D) Quantification of MAU2 protein levels on western blots of total cell lysates fro
dependent experiments ± SEM.
(E) Immunoprecipitation (IP) of NIPBL from nuclear extracts of HEK293 and HT108
down fromWT andNIPBLDN cells while MAU2 co-precipitated only inWT cells, m
strong signals in the MAU2 immunoblot are the IP antibodies.
Note that the blot for NIPBL C-terminal in HT1080 WT and clones are identical be
6 Cell Reports 31, 107647, May 19, 2020signal detected upon mutagenesis of aTIS2 suggests an ineffi-
cient usage of aTIS1. Accordingly, mutagenesis of both aTIS fully
abolished the signal.
The use of aTIS2 to initiate translation of NIPBLDN in mutant
cells restores the correct frame of the protein after the duplica-
tion of T, producing an isoform of NIPBL characterized by a
different Nterminus and a correct C terminus. Precisely, only
the first 12 amino acids differ from wild-type NIPBL.
However, we cannot rule out that, in the presence of a full-
length transcript, additional aTIS might be used from the ribo-
some to ensure maximal NIPBL yield. In any case, the alternative
isoforms are all predicted to be unable to interact with MAU2, as
the first 38 amino acids of NIPBL are mediating this interaction
(Braunholz et al., 2012). Consistently, NIPBLDN cells showed a
strong reduction of MAU2, most likely caused by its inability to
interact with NIPBL.
NIPBLDN Cells Do Not Display Cohesion Defects
NIPBL is well known for its role as cohesin loader. The canonical
function of the cohesin complex is the maintenance of sister
chromatid cohesion during bothmitosis andmeiosis. To address
whether the NIPBLDN protein is capable to support cohesin
loading without MAU2, we first tested cohesin’s function in sister
chromatid cohesion. We analyzed NIPBLDN and control cells by
spreading and Giemsa staining of mitotic chromosomes (Fig-
ure 5A). Normal cohesion was observed in 95% of HEK293 con-
trol cells and 92% and 87% in NIPBLDN c.1 and c.2 cells,
respectively. Differences were statistically significant only for
clone c.2 (p = 0.199 for c.1, p = 0.001 for c.2) (Figure 5B). For
HT1080 cells, we observed normal cohesion in 98.1% of wild-
type cells and in 99.7% and 99.4% of cells of NIPBLDN c.4
and c.15 clones (p = 0.018 for c.4 and p = 0.122 for c.15) (Fig-
ure 5C). We also determined the mitotic indices in the HEK293
and HT1080 clones and observed around 3% of mitotic cells in
all cell lines with only a slight increase to 4.5% in the HEK293
NIPBLDN c.2 clone (Figures 5D and 5E). In summary, we do
observe for HEK293 NIPBLDN cells a slight increase in defective
sister chromatid cohesion and an increasedmitotic index for one
clone. This is not recapitulated by the HT1080 cells. Therefore,
we concluded that the differences in HEK293 cells might be
due to clonal variation and that NIPBLDNexpression in combina-
tion with reduction of MAU2 levels leave chromatid cohesion
largely unaffected in mitotic cells.
Further analysis of sister chromatid cohesion in the HEK293
cells was performed by measuring the distance between paired
fluorescence in situ hybridization (FISH) signals in interphase
cells. We used a FISH probe that maps on chromosome
21q22.2, a locus that is tetrasomic in HEK293 cells and therefore
labels four pairs of sister chromatids in G2 cells (Figure 5F). In
wild-type cells, the average interchromatid distance was
0.57 mm. The presence of NIPBLDN in both NIPBL c.39dupm HEK293 and HT1080 NIPBLDN cells. Data are shown as mean of three in-
0WT and NIPBLDN cells and detection of NIPBL andMAU2. NIPBL was pulled
eaning that the residual MAU2 is unable to interact with NIPBLDN. Note that the
tween (C) and (E); in (E) one lane of the clone not used for IP was blanked out.
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Figure 4. An Alternative Translation Initiation Site in NIPBL
(A) An N-terminally truncated NIPBL (NIPBLDN) is produced in HEK293 c.39dup cells. A very small size difference was observed in the western blot betweenwild-
type and mutant proteins, indicating close proximity of the alternative translation initiation site (TIS) to the canonical ATG. Two new ATGs appear in the sequence
around the T duplication (red) after shifting the reading frame by one base pair (aTIS1 and aTIS2).
(B) To test the existence of an alternative translation start site in NIPBLDN cells, the first 651 bp of NIPBL (wild-type [WT] or with the c.39dup) were cloned into a
vector for IVTT with a 3xFLAG tag that was designed in frame with the WT sequence. Plasmids carrying mutations of the new putative aTIS, in addition to the
duplication of T, were also generated.
(C) All plasmids were used as templates in IVTT reactions, and the IVTT products were analyzed by western blotting using anti-FLAG antibodies. A FLAG signal
was detected in the IVTT products of theWTNIPBL sequence and of the NIPBL c.39dupmutant, confirming that an alternative TIS is used in the presence of the T
duplication. FLAGwas detectable with the aTIS1 mutation but wasmuch reduced in the aTIS2 mutation, pointing to aTIS2 as aTIS for NIPBLDN.Mutation of both
aTIS fully abolished the FLAG signal.
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OPEN ACCESSclones did not change the distance between FISH signals signif-
icantly (Figure 5G), indicating that sister chromatid cohesion in
postreplicative cells is not altered by the NIPBL c.39dup
mutation.
Altogether, these results indicate that sister chromatid cohe-
sion during interphase and mitosis is largely unaffected by the
presence of NIPBLDN and a strong reduction of MAU2 levels.
Cohesin Binding to Chromatin Is Not Affected in
NIPBLDN Cells
To evaluate whether and how the MAU2 deficiency and the
absence of the N terminus of NIPBL affect the abundance and
chromatin-binding ability of NIPBL and cohesin, we fractionated
wild-type and NIPBLDN cells (HEK293 c.1 and c.2) into total, sol-
uble and chromatin-bound fractions (Figure 6A). A modest
reduction of NIPBL and the strong reduction of MAU2 were
observed in all fractions of both NIPBLDN clones. No difference
in the total amount of chromatin-bound cohesin was observedbetween the two cell lines, indicating that cohesin complexes
can be loaded onto chromatin by N-terminally truncated NIPBL
and in the absence of MAU2.
Next, we tested whether the localization of NIPBL and cohesin
on chromatin is affected and performed chromatin immunopre-
cipitation followed by sequencing (ChIP-seq) for NIPBL and the
cohesin subunit SMC3. We called 23,194 SMC3 peaks in wild-
type cells and 21,984 peaks in NIPBLDN cells (Figure 6B; Fig-
ure S5A). The heatmaps comparing the peaks signals in wild-
type cells with the signal intensity in NIPBLDN cells showed a
slightly reduced signal in the NIPBLDN cells, an effect that is
more pronounced at weaker peaks. The distribution of the peaks
over different genomic features, however, is unchanged (Fig-
ure 6C). For NIPBL we called 2,681 peaks for wild-type cells
and 2,505 and 2,695 peaks for NIPBLDN clones 1 and 2, respec-
tively (Figure 6B; Figure S5B). The identified peaks do not show a
change in feature distribution (Figure 6C). To identify also NIPBL
binding sites where NIPBL is not in direct contact with DNA orCell Reports 31, 107647, May 19, 2020 7
A B C
E
F G
D
Figure 5. NIPBLDN Cells Do Not Display Cohesion Defects
(A) Representative images of the categories used to cluster the chromosome spreads. For normal cohesion, chromosomes contain a primary constriction and
sister chromatids are tightly connected at their centromeres (upper panel). For partial cohesion defects, chromosomes lack a primary constriction and sister
chromatids are abnormally spaced while still closely opposed to each other (middle panel). Complete separation of sister chromatids indicates full cohesion
defect (bottom panel).
(B andC) Frequency of the different cohesion phenotypes determined in HEK293 cells (B) and HT1080 cells (C), expressed as a percentage of total prometaphase
cells. Data are shown as means of three independent experiments ± SEM. p values obtained with the two-tailed, unpaired t test are indicated.
(D and E) Mitotic indices of wild-type and NIPBLDN mutant clones in HEK293 (D) and HT1080 (E) cells. Data are shown as means of three independent ex-
periments ± SEM. p values obtained with the two-tailed, unpaired t test are indicated.
(F) Representative image of interphase DNA FISH performed on NIPBLDN cells. Scale bar represents 10 mm.
(G) Quantification of the interphase DNA FISH shows that the distance between paired FISH signals is not affected, confirming the absence of cohesion defects.
p values obtained with the two-tailed, unpaired t test are indicated.
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OPEN ACCESSweakly bound to it, we used a ChIP-seq protocol involving pro-
tein-protein crosslinking in addition to formaldehyde crosslink-
ing. Here 14,198 peaks in wild-type cells and 9,124 peaks in
NIPBLDN cells (Figure S5B) were called. Heatmaps comparing
the peak signals in wild-type cells with NIPBLDN cells (Fig-
ure S5C) show that on all wild-type peaks we can still obtain
signal in NIPBLDN cells, indicating that a large number of the8 Cell Reports 31, 107647, May 19, 2020peaks in NIPBLDN is still present but just fell below the peak cut-
off. This is also supported by the notion that the overall distribu-
tion of the peaks over different genomic features is not altered
(Figure S5D). The results obtained by ChIP-seq were subse-
quently confirmed by ChIP-qPCR for SMC3 and NIPBL at
different genomic loci, confirming that cohesin- andNIPBL-bind-
ing sites are largely unchanged in NIPBLDN cells (Figure S6).
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to bind chromatin and to mediate normal cohesin loading onto
DNA despite the absence of MAU2. However, although the posi-
tion of the sites along the genome is not altered, a lower occu-
pancy was observed, consistent with the reduction of the chro-
matin-bound NIPBL fraction (Figure 6A).
NIPBLDN Cells Show Moderate Changes in Gene
Expression
NIPBL can influence gene expression directly or by loading the
cohesin complex on chromatin (Zuin et al., 2014). To test whether
the truncation of NIPBL triggers transcriptional changes, we per-
formed RNA sequencing for HEK293 wild-type cells and two
NIPBLDN clones, three replicates each. We observed a number
of differentially expressed genes that correlate well between
the two clones (Figure S7A). By correlating the transcriptome
data with the ChIP-seq signals for NIPBL, we could observe
that the coverage of the transcription start site (TSS) of downre-
gulated genes with NIPBL seems to be largely unchanged (Fig-
ure 6D). Signals of the cohesin subunit SMC3 was observed
only at the TSS of downregulated genes, and these signals ap-
peared to be slightly reduced in the NIPBLDN cells (Figure S7C).
This is consistent with the slightly reduced overall SMC3 binding
(Figure 6B). Applying stringent criteria to the RNA sequencing
data (p < 0.05; consistency between clones, |fold change [FC]|
> 2), we observed 31 upregulated genes and 257 downregulated
genes in the HEK293 NIPBLDN cells (Figure 6E; Tables S3 and
S4). Only two of the upregulated genes but 41 downregulated
genes have a NIPBL site near the promoter (± 1 kb around the
TSS). GO term analysis showed a broad range of terms related
to cell growth and development (Figure 6F), which would be
consistentwith the involvement ofNIPBLandcohesin indevelop-
ment. In summary, these results show that the rescue of kollerin
complex functions by alternative translation might not be com-
plete, as a number of genes seem to depend on the presence
of a wild-type NIPBL with intact N terminus and MAU2.
Cells of a CdLS Patient with an Early Splice Site
Mutation in NIPBL Show MAU2 Instability
To show that the observed rescue mechanism for NIPBL early
truncation mutations that leads to an alternative N terminus
and renders MAU2 largely dispensable is relevant for CdLS pa-
tients, we searched for cases in which this mechanism might
play a role.
We obtained LCLs from a patient with the clinical diagnosis of
mild CdLS (AG0885) that harbors a heterozygous early splice siteFigure 6. Cohesin Binding to Chromatin Is Not Affected in NIPBLDN C
(A) Fractionation of wild-type and NIPBLDN cells (c.1 and c.2) in soluble and chrom
soluble pool but also on chromatin in NIPBLDN cells. No differences in the amou
(B) The heatmaps depict normalized ChIP coverage observed in the SMC3 and NI
type and NIPBLDN cells. The heatmaps are centered on the peaks observed in w
(C) Distribution of the peaks observed in the SMC3 and NIPBL ChIP-seq experim
type and NIPBLDN cells. No striking differences are visible between wild-type an
(D) Plot showing the NIPBL coverage at promoters of genes downregulated in N
(E) Volcano plot showing the genes differentially expressed in NIPBLDN clone c
analyzed clones are shown. Genes with |FC| < 2 are colored orange. Genes with
shown.
(F) Gene Ontology term analysis of the genes shown in (E).
10 Cell Reports 31, 107647, May 19, 2020variant in NIPBL (c.358+1G>C) (hereafter termed NIPBL
c.358+1G>C cells). Similar mutations in two patients with mild
CdLS features have already been described and characterized
(Teresa-Rodrigo et al., 2014). Here, the c.358+1G>A substitution
led to the out-of-frame skipping of exon 4 of NIPBL, predicted to
result in a premature truncation of NIPBL after amino acid 77
(NIPBL truncation p.[Ile77Metfs*5]). We could confirm the skip-
ping of NIPBL exon 4 in the NIPBL c.358+1G>C cells by amplifi-
cation and sequencing of cDNA (data not shown) (Figure 7A).
Transcripts with such an out-of-frame deletion are thought to
be the target of nonsense-mediated mRNA decay, thereby lead-
ing to NIPBL haploinsufficiency. To test the relevance of
nonsense-mediated mRNA decay, we determined the total and
allele-specific NIPBL transcript levels in the NIPBL
c.358+1G>C cells and two healthy controls (LCLs AG0089 and
AG0096) (Figure 7B). Total NIPBL transcripts are not reduced
in the NIPBL c.358+1G>C cells (Figure 7C) and the allele-specific
real-time PCR suggested that the wild-type and themutant allele
are equally expressed in these cells (Figure 7D). Altogether,
these results corroborate the hypothesis that the NIPBL mutant
transcript does not undergo nonsense-mediatedmRNA decay in
the NIPBL c.358+1G>C cells.
To investigate the effect of this mutation on protein levels, we
analyzed NIPBL and MAU2 protein levels in nuclear extracts
from NIPBL c.358+1G>C cells and healthy controls (Figure 7E).
Despite the splice site mutation, NIPBL protein levels detected
with an antibody against the C terminus of NIPBL (isoform A) ap-
peared to be largely unchanged, whereas MAU2 protein levels
are reduced up to 50% in NIPBL c.358+1G>C cells (Figure 7F).
These observations are in line with our results from NIPBLDN
cells (HEK293 and HT1080). An alternative translation initiation
could prevent the reduction of NIPBL levels in NIPBL
c.358+1G>C cells. The resulting N-terminal truncation is too
small relative the full-length NIPBL protein to cause a visible mo-
lecular weight change. However, as demonstrated in the
NIPBLDN cells, an N-terminal truncation would affect the N-ter-
minal NIPBL residues interacting with MAU2. This would lead to
reduced MAU2 protein levels, as observed.
From a phenotypical point of view, the patient with NIPBL
c.358+1G>Cmutation and the two previously described patients
with the splicing mutation affecting nucleotide c.358+1 display
mild CdLS features (Teresa-Rodrigo et al., 2014; David Fitzpa-
trick, personal communication). Patients with truncating muta-
tions occurring later in the protein sequence are generally
characterized by moderate to severe phenotypes and often pre-
sent with limb anomalies (Selicorni et al., 2007). Hence, theells
atin-bound proteins shows a small reduction of NIPBL and loss of MAU2 in the
nts of soluble or chromatin-bound cohesin are observed.
PBL ChIP-seq experiments performed with formaldehyde crosslinking for wild-
ild-type cells, and the color intensity relates to normalized counts (RPKM).
ents over different genomic features (promoters, introns, exons, etc.) for wild-
d NIPBLDN cells.
IPBLDN cells.
.1. Only genes with the criterion p value < 0.05 and consistency between the
|FC| > 2 are displayed in blue, and the numbers of genes in this category are
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C E Figure 7. NIPBL Splice Site Mutation in
CdLS Leads to MAU2 Instability
(A) Scheme indicating the position of the NIPBL
splice site mutation c.358+1G>C and the resulting
splice product excluding exon 4. The qPCR
primers used to quantify the splice products are
indicated.
(B) NIPBL mutant and control LCLs used.
(C) Messenger RNA levels of NIPBL and MAU2 in
CdLS patient cells with NIPBL (c.358+1G>C) mu-
tation and controls were determined by RT-PCR/
qPCR relative to the housekeeping gene NADH.
For NIPBL, two intron-skipping primer pair at
opposite ends of the transcript were used (exons 2
and 3 and exons 40 and 41). SDs are from qPCR
replicates; p values were calculated for the three
controls and one patient using the unpaired t test
with Welch’s correction.
(D) Quantitation of the mRNA originating from the
correct splice product (left panel, primers
ex2_F+wt_R) and of the mutant splice product
(right panel, primers ex2_F+mutR). Data are
shown as mean of n = 3 experiments ± SEM. p
values obtained with the two-tailed, unpaired t test
are indicated as **p < 0.05, ***p < 0.005, and ****p <
0.0005.
(E) Nuclear extracts of controls (Ctrl.1 and Ctrl.2)
and of NIPBL c.358+1G>Cmutant cells (G>Cmut)
were analyzed by western blotting with antibodies against NIPBL (C-terminal antibody detecting isoform A), MAU2, and SMC2 and tubulin as loading controls.
(F) Quantitation of the MAU2 protein levels relative to tubulin and to Ctrl.1. **p < 0.05 (two-tailed, unpaired t test from n = 3 experiments).
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tects patients from the otherwise more severe consequences
arising from NIPBL haploinsufficiency.
DISCUSSION
MAU2 (Scc4 in S. cerevisiae) is a ubiquitously expressed protein
that interacts with NIPBL (Scc2 in S. cerevisiae) (Ciosk et al.,
2000; Seitan et al., 2006; Watrin et al., 2006) in a complex termed
kollerin. The interaction with NIPBL is crucial for MAU2 protein
stability and vice versa (Watrin et al., 2006). Kollerin is involved
in cohesin loading and transcriptional regulation (Ciosk et al.,
2000; Zuin et al., 2014). Mutations in NIPBL are the primary ge-
netic cause of CdLS, whereas alterations of its binding partner
MAU2 have not been reported so far (Mannini et al., 2013).
Here we describe the first genetic variant in MAU2 causing a
CdLS phenotype. The observed p.(Gln310_Ala316del) variant
in MAU2 impairs the interaction with NIPBL, possibly by distort-
ing the three-dimensional structure of MAU2. Consistently,
reduced affinity was observed between MAU2 and NIPBL with
in vitro assays in the presence of the in-frameMAU2 deletion de-
tected in the CdLS patient. The deletion in MAU2 lies in a ‘‘highly
conserved surface patch’’ described by Hinshaw et al. (2015) in
budding yeast Scc4. In yeast, mutations in this patch lead to a
plasmid segregation phenotype and reduced cohesin loading
at the centromere, while cohesin loading on chromosome arms
remained unaffected (Hinshaw et al., 2015). However, centro-
mere organization is fundamentally different between yeast
and human.
Therefore, we propose that this deletion exerts its deleterious
effects in a way comparable with mutations that directly affectthe NIPBL coding sequence and leads to NIPBL haploinsuffi-
ciency. In agreement with this proposition, the patient’s pheno-
type resembles the phenotype of the spectrum of NIPBL muta-
tions. The commonalities between the MAU2 and NIPBL
patients include typical CdLS facial dysmorphism, micro-
cephaly, intellectual disability, and delayed motor and verbal
development. Additionally, these patients also share similar
changes in gene expression patterns. A particular resemblance
stands out when comparing the phenotype of the MAU2
p.(Gln310_Ala316del) patient with a patient carrying the
p.(Gly15Arg) substitution inNIPBL, a mutation shown to interrupt
the interaction with MAU2 (Bot et al., 2017; Braunholz et al.,
2012). This resemblance further supports the hypothesis that
the deletion in MAU2 and the NIPBL missense mutation are
associated with similar downstream molecular consequences.
By further investigating the repercussions of early truncations
in NIPBL, we found that cells expressing an N-terminally trun-
cated form of NIPBL (NIPBLDN) are fully viable, although the
interaction with MAU2 that depends on the first 38 residues
(Braunholz et al., 2012) is impaired. As consequence, these cells
have nearly completely lost the MAU2 protein, in line with the
observation that depletion of NIPBL by RNA interference re-
duces MAU2 levels (Watrin et al., 2006). Similar observations
have been made by Haarhuis et al. (2017).
Molecular analyses of these cells indicated that NIPBLDN is
still able to bind chromatin and to mediate cohesin loading
onto DNA despite the almost total loss of MAU2. This observa-
tion is consistent with overexpression assays that demonstrate
that a N-terminally truncated form of NIPBL that is not capable
to interact with MAU2 can still be recruited to DNA damage sites
(Bot et al., 2017). In addition, it was reported that, in vitro, Scc2Cell Reports 31, 107647, May 19, 2020 11
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that of the kollerin complex and was able to mediate cohesin
loading (Murayama and Uhlmann, 2014), although another study
showed that Scc4 is required in budding yeast for in vivo recruit-
ment of Scc2 to chromatin (Chao et al., 2015). It was suggested
that the Scc2 N terminus, together with Scc4, is necessary to
localize kollerin to chromatin (Chao et al., 2015). Furthermore,
the N terminus of NIPBL was reported to be in contact with
SMC1A, while the interaction to RAD21 (Scc1 in S. cerevisiae)
is mediated by the C-terminal HEAT-repeat domain of NIPBL
(Chao et al., 2017). In NIPBLDN cells, cohesin and NIPBL
DNA-binding sites are largely unchanged, indicating that
NIPBLDN is fully capable to load and position cohesin. Cohesin
loaded by NIPBLDN also proved to be able to accomplish the
main function of the complex for centromere and chromosome
arm cohesion.
Does MAU2 have more functions besides stabilizing the
NIPBL N terminus in human cells? So far, NIPBLDN can fulfill
the roles of the kollerin complex despite its inability to interact
with MAU2. The specific roles shown for centromeric cohesin
in yeast is unlikely to be relevant in mammals. However, our tran-
scriptome analysis in NIPBLDN cells revealed a number of gene
expression changes, mostly downregulation, which cannot be
explained by reduced NIPBL coverage at promoters. Izumi
et al. (2019) similarly concluded that the NIPBL N terminus is
important for the transcriptional regulatory role of NIPBL. In
this view, MAU2 could have a role in fine-tuning the expression
of genes bymodulating kollerin’s interactionwith other transcrip-
tion factors localizing to these promoters (Zuin et al., 2014).
CdLS is characterized by extensive clinical variability, and pa-
tients present with a wide range of phenotypes (Kline et al.,
2007). Heterozygous out-of-frame deletions and insertions or
nonsense variants in NIPBL are associated mainly with severe
phenotypes and with the presence of limb malformations (Seli-
corni et al., 2007). However, truncating mutations affecting
exons 2–9 of NIPBL are associated with a lower frequency of
limb reductions or malformations and often result in phenotypes
that are milder than expected in comparison with truncating mu-
tations affecting exons 11–47 (Borck et al., 2004; Nizon et al.,
2016; Oliveira et al., 2010). Our genome editing experiments
demonstrated that cells with early truncations in NIPBL adopt
a protective mechanism on the basis of alternative translation
initiation in order to minimize the otherwise deleterious effects
of mutations, thus offering an explanation for the milder pheno-
types of these patients. Translation re-initiation is a widespread
mechanism for escaping nonsense-mediated mRNA decay in
human genes (Lindeboom et al., 2016). In most cases, the dis-
tance between the original start codon and the premature termi-
nation codon can be considered a strong predictor of the ability
to escape nonsense-mediated mRNA decay (Lindeboom et al.,
2016). In our cells, the choice of the new TIS appears to be
dependent on the nucleotide sequence surrounding the variant
of interest, thereby rendering this protective mechanism muta-
tion- specific. It is conceivable that the CdLS cells carrying the
NIPBL splicing mutation that leads to skipping of exon four
(c.358+1G>C), and that is predicted to insert an early stop codon
after 5 amino acids, might use a different aTIS than the one used
by the NIPBLDN cells, which harbor a frameshift mutation in12 Cell Reports 31, 107647, May 19, 2020exon 2. This rescuemechanism ensures the synthesis of thema-
jor part of NIPBL at the expense of its N terminus, which appears
to be dispensable for cell survival. Congruent with this hypothe-
sis, cap analysis of gene expression (CAGE) data suggest the ex-
istence of an alternative TSS in exon 10 ofNIPBL (http://fantom3.
gsc.riken.jp/). A recent study also demonstrated that cells could
tolerate disruptive mutations up to exon 10, indicating that the
region between exons 11 and 47 alone is able to accomplish
themain tasks of NIPBL and is therefore essential for cell survival
(Haarhuis et al., 2017). Additionally, the existence of an N-termi-
nal truncation of NIPBL has been proved in physiological condi-
tions in yeast, where the cell cycle-dependent cleavage of the
first 150 amino acids regulates the spatiotemporal association
of cohesin with chromatin (Woodman et al., 2014). In the case
we present here, however, alternative translation initiation was
observed only in the presence of a deleterious mutation in the
NIPBL transcript. Mutations in MAU2 that impair kollerin com-
plex stability, like the one reported in this paper, would not be ex-
pected to trigger such protective mechanism.
In summary, our data strongly indicate the existence of a pro-
tectivemechanism preventing a total loss of NIPBL gene product
by the use of alternative start codons in transcripts with early
truncating mutations. Such translation re-initiation could ac-
count for a proportion of patients who carry truncating mutations
in NIPBL and exhibit unexpectedly mild phenotypes, but might
also apply to other genetic conditions. Amore exhaustive under-
standing of the molecular mechanisms triggering this rescue
could help define a better genotype-phenotype correlation and
could open perspectives for translational approaches.STAR+METHODS
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BCA protein assay kit Thermo Fisher Scientific 23225
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Superscript III Reverse Transcriptase Thermo Fisher Scientific 18080093
qPCRBIO Probe Mix Hi-ROX assay PCR Biosystems PB20.26-05
TnT Quick coupled transcription/translation system Promega L1170
NEXTFlex ChIP-seq kit BioO Scientific NOVA-5143-01
DNeasy Blood & Tissue kit QIAGEN 69506
Lipofectamine RNAiMAX Thermo Fisher 13778100
TruSeq DNA PCR-Free kit Illumina 20015963
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N/A
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N/A
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pcDNA 3.1/myc-His B Thermo Fisher Scientific V80020
pCMV-BD Agilent Technologies #211342
pCMV-AD Agilent Technologies #211343
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Picard v1.97 Broad Institute http://broadinstitute.github.io/picard/
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ngsplot
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packages/release/bioc/html/
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Bcl2fastq v2.17 Illumina https://support.illumina.com/
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Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Kerstin S.
Wendt (k.wendt@erasmusmc.nl).
Materials availability
All plasmids and cell lines generated in this study are available on request from the Lead Contact without restriction.
Data and code availability
The accession number for the ChIP-sequencing datasets reported in this paper is Gene Expression Omnibus (GEO): GSE122299.
The accession number for the RNA-sequencing data reported in this paper is SRA archive: PRJNA609330.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human subjects
Whole exome sequencing was performed on a selected group of 15 patients with a clinical diagnosis of CdLS, comprising five fe-
males and tenmales. Age of patients ranged from 7 to 32 years. All procedures including patients were approved by the Ethical Com-
mittee of the University of L€ubeck (approval number for human studies HL07-158) and were performed in accordance with the ethical
standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or
comparable ethical standards. Informed consent was obtained from all individuals participants included in this study.
Detailed characterization of the MAU2 patient
The patient with the MAU2 mutation is currently 14 years old. This patient was born at 34 weeks of gestation after caesarean section
from healthy and non-consanguineous parents. Intra-uterine growth retardation was detected at the 30th week of pregnancy. At
birth, Apgar scores were 5 and 8 at 1 and 5 minutes, respectively. Birth weight was 1330 g (2.46 SD), birth length was 39.5 cm
(2.42 SD) and the occipital frontal circumference was 27 cm (3.17 SD). He showed early feeding difficulties and developed a
generalized spasticity from the very first weeks of life, which severely affected his mobility and soon required the use of a wheelchair.
At the age of two years he was diagnosed with Cornelia de Lange syndrome because of his facial features and the diagnosis was
confirmed by different experts independently. His facial features were typical for the syndrome and included microcephaly, brachy-
cephaly, low anterior and posterior hairline, arched eyebrows, synophrys, long eyelashes, ptosis, flat nasal bridge, long and smooth
philtrum, thin lips with downturned corners of the mouth and highly arched palate. In addition, he presented with hypertelorism,
myopia, low-set and posteriorly rotated ears, small feet, clinodactyly of the fifth finger, hirsutism and cryptorchidism. He developed
very early gastresophageal reflux disease. Magnetic Resonance Imaging revealed the existence of a thin corpus callosum, a mild
ventriculomegaly and periventricular cysts. Last evaluation was performed at the age of 10 years. At this age, weight was 18.8 kg
(4.5 SD), height was 121 cm (4.96 SD) and the occipital frontal circumference was 47 cm (4.96 SD). He presented with severe
intellectual disability and delayed speech and motor development. He pronounced his first words at the age of two years but had no
further verbal development. Currently, he is still not able to sit unassisted or to walk. This patient was found to carry an in-frame dele-
tion of 21 nucleotides in MAU2, resulting in the loss of seven amino acids: RefSeq NM_015329, c.927_947del, p.(Gln310_Ala316del).e3 Cell Reports 31, 107647, May 19, 2020
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HEK293 cells (female) were cultured in DMEM supplemented with 10% FBS and 1% Antibiotics and grown at 37C with 4% CO2.
HT1080 cells (male) were cultured in DMEM supplemented with 10% FBS and 1% Antibiotics and grown at 37C with 4% CO2.
Control fibroblast and patient’s fibroblasts were cultured in DMEM supplemented with 10% FBS and 1% Antibiotics and grown at
37C with 4% CO2.
Control LCLs and patient’s LCL were cultured in RPMI supplemented with 10% FBS and 1% Antibiotics and grown at 37C with
4% CO2.
METHOD DETAILS
CRISPR/Cas9
Genome editing was performed as described by Ran and colleagues in 2013 (Ran et al., 2013). In detail, two different 20 nucleotides
guide sequences followed by a 50-NGG PAM and complementary to exon 2 of NIPBL (Biomers, Ulm, Germany, primers available
upon request) were inserted into the pSpCas9(BB)-2A-Puro (PX459) V2.0 vector (#62988, Addgene, Cambridge, MA, USA).
HEK293 cells were transfectedwith the resulting plasmids with the TaKaRa Xfect Transfection Reagent (Clontech-Takara, Saint-Ger-
main-en-Laye, France), following the manufacturer’s instructions. 24 hours post-transfection, selection of positively transfected
clones was performed for 48 hours with DMEMmedium supplemented with 10% FBS, 1% Antibiotics and puromycin at a final con-
centration of 8 mg/ml (Thermo Fisher Scientific). After selection, single clones were picked and expanded.
Protein isolation and quantification
Cells were lysed using RIPA buffer ph 7.6 (50 mM HEPES, 1 mM EDTA, 1% NP-40, 0.5M LiCl) and a protease inhibitor cocktail
(Roche, Mannheim, Germany). Protein concentration was determined through the BCA Protein Assay Kit (Thermo Fisher Scientific)
according to the manufacturer’s protocol with the Tristar2 Multimode Reader LB942 (Berthold Technologies, Bad Wildbad,
Germany).
RNA isolation, cDNA synthesis and Real-Time PCR
RNA extraction was performed with the ReliaPrep RNACell Miniprep System (Promega, Mannheim, Germany) according to theman-
ufacturer’s instructions. Subsequent treatment with DNase I (RNase-free, New England Biolabs, Frankfurt am Main, Germany) was
carried out on all RNA samples in order to avoid genomic DNA contaminations.
The SuperScript III Reverse Transcriptase (Thermo Fisher Scientific) was used to retro-transcribe 2 mg of RNA with random hex-
amers. cDNA synthesis was performed in two independent experiments for each sample.
The expression level of the transcripts of interest was assessed by the use of the Real-Time PCR qPCRBIO Probe Mix Hi-ROX
assay (PCR Biosystems, London, UK). The investigation was run on the 7300 Real-Time PCR system (Thermo Fisher Scientific).
The following TaqMan gene expression assays were used for the analysis: Hs01062386_m1, Hs00209846_m1 and
Hs01122291_m1 (Thermo Fisher Scientific). Based on efficiency experiments, the GAPDH or NADH genes were selected as endog-
enous normalizer and amplified with the TaqMan gene expression assay ID Hs02758991_g1 and Hs00190020_m1 (Thermo Fisher
Scientific). Relative gene expression was determined using the DDCt method (Livak and Schmittgen, 2001).
Protein degradation pathways
Wild-type and CRISPR/Cas9 HEK293 cells were treated with the proteasome inhibitor MG132 for 4-8 hours (10 mM; Sigma Aldrich),
with the lysosome inhibitor ammonium chloride for 3-6 hours (NH4Cl, 20 mM; Millipore, Darmstadt, Germany) or with the autophagy
inhibitor Bafilomycin for 3-6 hours (100 nM, Sigma Aldrich).
In vitro transcription-coupled translation
In Vitro Transcription-coupled Translation (IVTT) reactions were performed with the TnT Quick Coupled Transcription/Translation
System (Promega) starting from 500 ng of plasmid, following the manufacturer’s instructions.
Subcellular fractionation
HEK293 cells were collected off the plates and washed twice with ice-cold PBS. The final cell pellet was resuspended in extraction
buffer (20 mMTris pH 7.5, 100 mM sodium chloride, 5 mM magnesium chloride, 0.2% NP-40, 10% glycerol, 0.5 mM dithiothreitol)
supplemented with tablets of protease inhibitors (Roche) and phosphate inhibitors (10 mM sodium fluoride, 20 mM b-glycerophos-
phate). Cells were lysed on ice by passage through a 26-gauge needle. Lysates were incubated for 10 minutes on ice and were then
centrifuged (21,000 g, 15 minutes, 4C) for collection of the soluble protein extract. The chromatin-containing pellet was washed six
times with extraction buffer (8,000 g, 3 minutes, 4C) and then directly resuspended in sample buffer.Cell Reports 31, 107647, May 19, 2020 e4
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The following siRNA oligos were used to perfrom knockdowns for MAU2 and NIPBL:
Control non-targeting
sense CGUACGCGGAAUACUUCGAtt
antisense UCGAAGUAUUCCGCGUACGtt
NIPBL
sense GCAUCGGUAUCAAGUCCCAtt
antisense UGGGACUUGAUACCGAUGCtt
MAU2
sense GCAUCGGUAUCAAGUCCCAtt
antisense UGGGACUUGAUACCGAUGCtt
SiRNA knockdown was performed with Lipofectamine RNAiMAX using the reverse transfection protocol. Cells were harvested for
analysis at 72 hours after transfection.
ChIP-sequencing
Chromatin immunoprecipitation for SMC3 was performed as previously described (Wendt et al., 2008). In brief, cells at 70%–80%
confluence were crosslinkedwith 1% formaldehyde for 10minutes and quenchedwith 125mMglycine. After washingwith PBS, cells
were resuspended in lysis buffer (50 mM Tris-HCl pH 8.0, 1% SDS, 10 mM EDTA, 1 mM PMSF and Complete Protease Inhibitor
(Roche)) and sonicated (Diagenode Bioruptor, Seraing, Belgium) to around 500 bp DNA fragments. Debris were removed by centri-
fugation and the lysate was diluted 1:4 with IP dilution buffer (20mMTris-HCl pH 8.0, 0.15MNaCl, 2mMEDTA, 1%TX-100, protease
inhibitors) and precleared with Affi-Prep Protein A support beads (Bio-Rad). The respective antibodies were incubated with the lysate
overnight at 4C, followed by 2 hours incubation at 4Cwith blocked protein A Affiprep beads (Bio-Rad) (blocking solution: 0.1 mg/ml
BSA). Beads were washed with washing buffer I (20 mM Tris-HCl pH 8.0, 0.15 M NaCl, 2 mM EDTA, 1% TX-100, 0.1% SDS, 1 mM
PMSF), washing buffer II (20 mM Tris-HCl pH 8.0, 0.5 M NaCl, 2 mM EDTA, 1% TX-100, 0.1% SDS, 1 mM PMSF), washing buffer III
(10 mM Tris-HCl pH 8.0, 0.25 M LiCl, 1 mM EDTA, 0.5% NP-40, 0.5% sodium deoxycholate) and TE-buffer (10 mM Tris-HCl pH
8.0,1 mM EDTA). Beads were eluted twice (25 mM Tris-HCl pH 7.5, 5 mM EDTA, 0.5% SDS) for 20 minutes at 65C. The eluates
were treated with proteinase K and RNase for 1 hour at 37C and decrosslinked at 65C overnight. The samples were further purified
by phenol-chloroform extraction and ethanol-precipitated. The pellet was dissolved in TE buffer.
For NIPBLChIP-seq experiments two different protocols were applied. Initially, we used a previously published protocol employing
only formaldehyde crosslinking (FA-xlink) (Zuin et al., 2014). Subsequently, we employed a protocol (DSG/FA-xlink) adapted from van
den Berg et al. (van den Berg et al., 2017) that has been shown to allow efficient detection of weaker NIPBL binding sites. For this
second protocol, before crosslinking with formaldehyde, cells underwent a protein-protein crosslinking step. In brief, cells were sus-
pended in PBS and treaded for 45 minutes at room temperature under rotation with 2 mM disuccinimidyl glutarate (DSG). After three
washes with PBS, cells were crosslinked with formaldehyde as described above. Sonication and pull-down were performed as
described above with modifications of the beads washing steps according to Kagey et al. (Kagey et al., 2010). Beads were washed
once with the IP dilution buffer, once with 20mM Tris-HCl pH8, 500mM NaCl, 2mM EDTA, 0.1% SDS, 1%Triton X-100, once with
10mM Tris-HCl pH8, 250nM LiCl, 2mM EDTA, 1% NP40 and once with TE buffer containing 50 mM NaCl.
For sequencing, the DNA libraries were prepared using the NEXTFlex ChIP-Seq kit (BioO Scientific, Austin, TX, USA). These li-
braries were sequenced according to the Illumina TruSeq v3 protocol on an Illumina HiSeq2500 sequencer (Illumina, San Diego,
CA, USA). Single reads were generated of 50 base pairs in length. The quality of DNA sequence was investigated using FASTQC
(version 0.11.2), and, when necessary trimmomatic (version 0.32) was used to remove low-quality reads and regions. Quality
controlled sequence was aligned to Human genome (hg19) using bowtie (version 1.0.0), and samtools (version 0.1.19) was used
to remove reads with mapping quality less than 30, and to keep only aligned reads. Duplicated reads were removed, after alignment,
using Picard (version 1.97). For statistics of the ChIP-sequencing see Table S6. Peaks were called using MACS (macs 2) and Peaks
were filtered using P value. UCSC tracks were generated after duplicate removal, using HOMER (version 4.3) and deeptools (version
3.0.2). Heatmaps were generated using Deeptools (version 3.0.2) and NGS plot (version 2.61). Peaks were annotated to specific re-
gions using ChIPseeker (Bioconductor package version 1.14.2). The data are accessible at GSE122299.
ChIP-qPCR
For ChIP-qPCR experiments the ChIP for IgG control, SMC3 and NIPBL (NIPBL #1 antibodies) were performed as described above
for the SMC3 ChIP-seq experiment. qPCR analysis using Platinium taq (Thermo Fisher Scientific) was performed according to the
manufacturer’s instructions and analyzed using a CFX96 C1000 Thermal cycler (Bio-Rad) using the qPCR primers listed in Table S2.e5 Cell Reports 31, 107647, May 19, 2020
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Cells were treated for 90 minutes with 100 ng/ml of nocodazole. Cells were collected and resuspended in 1 mL of medium. 1.5 mL of
tapwater was added. 6minutes later 7mL of Carnoy fixative (3:1,methanol: glacial acetic acid). Cells were then spread on glass slide,
dried, stained with Giemsa stain and mounted in Entellan. Mitotic chromosome spreads were observed using a light microscope
(DM2000 Leica, France) with a 40x dry objective.
Determination of the mitotic index
Cells were grown on coverslips to maximal 60% confluency, fixed and mounted with Vectashield DAPI. Cells in metaphase and telo-
phase were identified according to their morphology. Between 500 to 900 cells were counted per cell line in three different replicates.
Fluorescence in situ hybridization (FISH)
DNA FISH was performed as previously described (Schmitz et al., 2007), with the exception that cells were fixed as described above
and processed for FISH after spreading on glass slides. Only pairs for which the dots could be clearly resolved were considered in the
analysis. Microscopic image acquisitions were performed on a Zeiss Axio Imager M2 using 63X oil-immersion objective. Image anal-
ysis was performed using ImageJ software.
Whole Genome Sequencing
Genomic DNA isolation was performed from blood with the DNeasy Blood & Tissue Kit (QIAGEN, Hilden, Germany) according to the
manufacturer’s instructions. Genomic DNA quantity was assessed using the Qubit dsDNA BR Assay Kit (Thermo Fisher Scientific).
For library preparation, 1000 ng of genomic DNAwere used together with the TruSeq DNA PCR-Free Kit (Illumina) following the man-
ufacturer’s recommended protocol. The genomic DNA was fragmented to an average length of 350 bp by sonication on a Covaris
E220 instrument (Covaris Inc., Woburn, MA, USA). Library preparation was performed in an automatedmanner using the NGSOption
B (Agilent Technologies, Santa Clara, CA, USA). We assessed the library quality and absence of primer dimers by running a Bio-
analyzer DNA High Sensitivity chip. Library quantification was performed using qPCR together with the Kapa Library Quantification
Illumina/Light Cycler 480 (Roche). The validated libraries were pooled in equimolar quantities and sequenced via 150 bp paired-end
on an Illumina HiSeq 4000 platform following Illumina’s recommended protocol. Raw data were demultiplexed with the Illumina
bcl2fastq 2.17 into individual fastq files. Reads were aligned using the mem algorithm of bwa 0.7.8 and aligned to the hg19 reference
into which decoy sequences had been added, PAR regions had beenmasked and themitochondrial DNA had been replacedwith the
rCRS (revised Cambridge Reference Sequence) to matchMITOMAP andmost publicly available resources for mtDNA variants. Base
quality scores were recalibrated using GATK BaseRecalibrator with enlarged context size for SNVs and Indels with respect to default
(4 and 8 base pairs instead of 2 and 3). Variant calling was then performed using first HaplotypeCaller, to produce an individual GVCF
file, and thenmultisample calling was performed using CombineGVCFs and then GenotypeGVCFswhich produced the actual variant
calls. Variant qualities and filters were then assessed with VariantRecalibrator tool using the tracks from GATK bundle and variants
from GnomAD. For de novo variants, the Genotype Refinement workflow was applied using GenotypePosteriors to which a PED file
with the family relationships, and again, aGnomAD trackwith allele counts and frequencies were supplied. The two subsequent steps
were VariantFiltration to exclude low quality genotypes and VariantAnnotator to annotate possible de novo in the final VCF file.
Mammalian two-hybrid assay
A fragment of NIPBL containing amino acids 1–300 was inserted into the pCMV-BD expression plasmid (#211342, Agilent Technol-
ogies, Santa Clara, CA, USA). The full-length open reading frame of MAU2 was cloned into the pCMV-AD plasmid (#211343,
Agilent Technologies). MAU2 mutant constructs containing the deletion identified in the patient of our cohort (c.927_947del21;
p.(Gln310_Ala316del)) were generated by site-directed in vitro mutagenesis with the Quick Change Site-directed mutagenesis kit,
according to the manufacturer’s instructions (Agilent Technologies). HEK293 cells were transiently transfected in 24-well plates
with FuGene-HD (Promega), according to the manufacturer’s instructions. Each well was transfected with 250 ng of the pCMV-
BD-NIPBL1-300aa, 250 ng of the pCMV-MAU2 wild-type or mutant constructs, 250 ng of the Firefly Luciferase reporter plasmid
(Promega) and 2,5 ng of the phRG-TK Renilla luciferase expression plasmid (Promega). Activity of Firefly and Renilla luciferases
wasmeasuredwith the Dual Luciferase Reporter Assay System (Promega) with the Tristar2Multimode Reader LB942 (Berthold Tech-
nologies). All measurements were performed in triplicate in at least three independent experiments. Relative luciferase activity,
indicating the strength of the interaction, was determined as the triplicate average of the ratio between the Firefly and the Renilla lucif-
erase activity.
Yeast two-hybrid assay
The first 300 amino acids of NIPBL and the wild-type and mutant full-length MAU2 were cloned into the Matchmaker GAL4 Two-
Hybrid System 3 (Clontech-Takara) pGBKT7 and pGADT7 plasmids, respectively, to obtain NIPBL–GAL4 BD or MAU2–GAL4 AD
fusion proteins. Yeasts (AH109) were co-transformed with the NIPBL and MAU2 fusion proteins, according to the Matchmaker 3
manual. Growth selection assays were performed using SD agar plates lacking Trp, Ade, His and Leu to detect interacting
transformants.Cell Reports 31, 107647, May 19, 2020 e6
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Patient fibroblasts seeded on a coverslip were exposed to 1 Gy g-irradiation using a 300kV ceramic X-ray tube (RS320 X-ray ma-
chine, Xstrahl). Cells were fixed according to standard immunofluorescence staining protocol and stained with anti-g-H2AX anti-
bodies (Invitrogen, 14-9865-80) and Alexa Fluor 488-conjugated goat anti-mouse secondary antibodies (Invitrogen, A11029). Images
were acquired using an immunofluorescence microscope (Zeiss Imager Z.1). The average number of g-H2AX foci for at least 50 cells
per cell line per time point were counted using ImageJ/FIJI software.
RNA-sequencing
Strand specific, polyA-enriched RNA sequencing was performed as described earlier (Haack et al., 2013). Briefly, RNA was isolated
from whole-cell lysates using the AllPrep RNA Kit (QIAGEN) and RNA integrity number (RIN) was determined with the Agilent 2100
BioAnalyzer (RNA 6000 Nano Kit, Agilent). For library preparation, 1 mg of RNA was poly(A) selected, fragmented, and reverse tran-
scribedwith the Elute, Prime, FragmentMix (Illumina). A-tailing, adaptor ligation, and library enrichment were performed as described
in the TruSeq Stranded mRNA Sample Prep Guide (Illumina). RNA libraries were assessed for quality and quantity with the Agilent
2100 BioAnalyzer and the Quant-iT PicoGreen dsDNA Assay Kit (Life Technologies). RNA libraries were sequenced as 150 bp
paired-end runs on an Illumina HiSeq4000 platform. The STAR aligner (Dobin et al., 2013)(v 2.4.2a) with modified parameter settings
(–twopassMode = Basic) was used for split-read alignment against the human genome assembly hg19 (GRCh37) and UCSC known-
Gene annotation. To quantify the number of reads mapping to annotated genes we used HTseq-count (Anders et al., 2015) (v0.6.0).
FPKM (Fragments Per Kilobase of transcript per Million fragments mapped) values were calculated using custom scripts. Differential
expression analysis was performed using the R Bioconductor package DESeq2 (Love et al., 2014).
For a statistic on the RNA-sequencing experiments see Table S7.
Gene ontology term enrichment analysis
Genes found to be differentially expressed (P value < 0.05, |Fold change| > 2) as compared to wild-type were considered in the an-
alyses. Term enrichment analysis was performed using WEB-based GEne SeT AnaLysis Toolkit in its 2019 version (Liao et al., 2019).
Over-Representation Analysis method was used on the Biological Processes functional database against genome protein-coding
reference set, with default parameters). Redundancy in rendered term list was reduced by weighted set cover method.
QUANTIFICATION AND STATISTICAL ANALYSIS
Real-Time PCR experiments were performed in triplicate for each sample; values with standard deviations exceeding 0.5% or stan-
dard errors exceeding 0.3%were excluded and the experiments were repeated. The bilateral unpaired t test was applied to compare
gene expression data, and differences between experimental groups were considered significant when p < 0.05. Specific p values
are stated in Figure 3.e7 Cell Reports 31, 107647, May 19, 2020
